奈达铂及顺铂胸腔灌注治疗非小细胞肺癌恶性胸腔积液的临床疗效及预后对比  

Comparison of The Clinical Efficacy and Prognosis of Nedaplatin and Cisplatin in the Treatment of Malignant Pleural Effusion Associated with Non-Small Cell Lung Cancer

作　　者：朱姝 刘淮东[1] 杨秋云[1] 李娟[1] 王惠[1] Zhu Shu;Liu Huai-dong;Yang Qiu-yun;Li Juan;Wang Hui(Department of Oncology,Second People's Hospital of Huaian City,Huaian 223001,China)

机构地区：[1]淮安市第二人民医院肿瘤内科,淮安223001

出　　处：《湖南师范大学学报（医学版）》2022年第1期163-166,共4页Journal of Hunan Normal University(Medical Sciences)

摘　　要：目的:对比奈达铂及顺铂胸腔灌注治疗非小细胞肺癌相关恶性胸腔积液的临床疗效及预后。方法:收集2015年1月~2018年2月本院经治非小细胞肺癌合并恶性胸腔积液者80例,随机分为奈达铂组(40例)与顺铂组(40例)。两组均在彩超引导下置入胸腔引流管并注入相应化疗药物。监测并记录灌注后临床疗效、药物相关不良事件、生活质量改善情况(Kamofsky评分)。灌注后随访1年,记录死亡及病情复发情况等。对数据进行统计分析。结果:两组完全缓解率、部分缓解率、无进展率及进展率间差异具有统计学意义。两组患者在恶心、呕吐、胸痛、中性粒细胞减少、谷丙转氨酶升高及尿素升高各分度发生率间差异具有统计学意义。两组灌注治疗1年后生存率差异无统计学意义。两组灌注治疗后1年恶性胸腔积液复发率差异无统计学意义。奈达铂组治疗后Kamofsky评分高于顺铂组,差异具有统计学意义。结论:奈达铂比顺铂可更好缓解恶性胸腔积液的临床症状,改善整体生活质量,减少药物不良反应,但在改善整体生存率及降低恶性胸腔积液复发率方面两者无差异。Objective To compare the clinical efficacy and the prognosis of nedaplatin with that of the cisplatin in the treatment of malignant pleural effusion associated with non-small cell lung cancer.Methods Eighty patients with malignant pleural effusion associated with non-small cell lung cancer,treated in our hospital from January 2015 to February 2018,were collected.All patients were divided into the nedaplatin group(40 cases)and the cisplatin group(40 cases),randomly.Both groups were placed the chest drainage tube under the guidance of ultrasonography,and then the corresponding drugs were injected.Clinical efficacy,drug-related adverse events,and Kamofsky score were monitored and recorded.1-year follow-up was performed.The death rate and the recurrence of malignant pleural effusion was recorded.Statistical analysis was performed.Results There are significant differences among complete response rate,partial response rate,progression-free rate and progression rate.There were significant differences between two groups in the incidence of nausea,vomiting,chest pain,neutropenia,alanine aminotransferase and urea elevation.There was no significant difference in survival rate between two groups after a year of perfusion.There was no significant difference in the recurrence rate of malignant pleural effusion between two groups.The Kamofsky score was higher in the nedaplatin group than that in the cisplatin group.Conclusion Compared with cisplatin,nedaplatin can better alleviate the clinical symptoms of malignant pleural effusion,improve the overall quality of life and reduce the incidence of drug-related side effects,but there is no difference inimproving the overall survival rate and reducing the recurrence rate of malignant pleural effusion.

关 键 词：奈达铂 顺铂 胸腔灌注 非小细胞肺癌 恶性胸腔积液 疗效 预后 

分 类 号：R734.2[医药卫生—肿瘤]